Opinion: Independent third-party entities as a model for validation of commercial antibodies.

Volume:Pages
65:1-8
Site
Toronto
Pubmed id
34246180
Authors

Laflamme C, Edwards AM, Bandrowski AE, McPherson PS

DOI
10.1016/j.nbt.2021.07.001
Journal
N Biotechnol
Publication Date
2021-7-7
Year
2021
N Publication Date
PI authors
McPherson
Laflamme
Validated
Y